Φορτώνει......
Biosimilars: the process is the product. The example of recombinant streptokinase
BACKGROUND: Worldwide, streptokinase remains the most used thrombolytic agent for the treatment of myocardial infarction. Recombinant streptokinase, from E. coli, is increasingly used in developing countries as a biosimilar of native streptokinase; however, potency assignments relative to the WHO In...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | J Thromb Haemost |
|---|---|
| Κύριοι συγγραφείς: | , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
BlackWell Publishing Ltd
2014
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4241032/ https://ncbi.nlm.nih.gov/pubmed/24913658 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jth.12629 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|